Evidence map›Paper›PMID 40076215›Full record

ArticleMolecules (Basel, Switzerland)2025

Towards Imaging Tau Hyperphosphorylation: Is DYRK1A a Potential Target for Imaging Hyperphosphorylation of Tau? Molecular Modeling Assessment and Synthesis of [

Cayz G Paclibar, Deanna M Schafer, Agnes P Biju, Fariha Karim, Stephanie A Sison, Christopher Liang, Shamiha T Ahmed, Jogeshwar Mukherjee

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Evaluation of [Acta neuropathologica communications · 2026
    Article
  2. Article
  3. Article
  4. Evaluation of [Research square · 2026
    Article
  5. Synthesis and Evaluation of Radioiodinated [Journal of labelled compounds & radiopharmaceuticals · 2026
    Article
  6. [Synapse (New York, N.Y.) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Cayz G PaclibarPreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA.ORCID 0009-0008-7853-5335
Deanna M SchaferPreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA.ORCID 0009-0001-7817-7944
Agnes P BijuPreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA.ORCID 0009-0007-0267-2299
Fariha KarimPreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA.ORCID 0009-0001-3104-9523
Stephanie A SisonPreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA.ORCID 0009-0007-1302-3219
Christopher LiangPreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA.ORCID 0000-0001-9081-294X
Shamiha T AhmedPreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA.
Jogeshwar MukherjeePreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA.ORCID 0000-0003-1009-877X

Funding

Novel Tau-Targeted Radiohalogenated Agents for Alzheimer's DiseaseR01AG077700 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI Jogeshwar Mukherjee · 2024 to 2026
$2.1M
NIA NIH HHS R01 AG077700NIH HHS R01 AG077700
6 · The paper itself

Abstract

Dual specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A), a phosphorylation kinase, is localized within the central nervous system and is linked to hyperphosphorylation of Tau. Imaging of DYRK1A may provide an earlier biomarker for Tauopathies, including Alzheimer's disease (AD). We have used Chimera-Autodock to evaluate potential molecules for binding to the binding site of DYRK1A. Five molecules, 10-bromo-2-iodo-11

Indexed as

Iodine RadioisotopesProtein Kinase InhibitorsProtein Serine-Threonine KinasesProtein-Tyrosine Kinasestau ProteinsAlzheimer DiseaseBinding SitesDyrk KinasesHarmineHumansModels, MolecularMolecular Docking SimulationPhosphorylationProtein BindingDyrk KinasesHarmineIodine-125Iodine RadioisotopesProtein Kinase InhibitorsProtein Serine-Threonine KinasesProtein-Tyrosine Kinasestau Proteins[125I]IPPI[125I]KuFal184Alzheimer’s diseaseautoradiographydown syndromeDYRK1Apost-mortem human Tau

Identifiers

PMID40076215
PMCPMC11901962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.